OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Stock Information for Longeveron Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Longeveron Inc.

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
Lineage Announces Formation of Scientific Advisory Board
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.